Biliary lipid secretion in chronic cholestatic liver disease*

Y A KESÄNIEMI, M P SALASPURO, M VUORISTO, and T A MIETTINEN†

From the Second Department of Medicine, University of Helsinki, Helsinki, Finland

SUMMARY  Biliary lipid secretion rates, faecal steroids, and serum lipids were studied in patients with chronic cholestatic liver disease mainly primary biliary cirrhosis. The biliary secretion of cholesterol, bile acids, and phospholipids was markedly decreased as compared with those in the control group and in general correlated negatively with the serum cholesterol and triglyceride values. The molar percentage of cholesterol was increased in the hepatic bile. This suggests that, in cholestatic liver disease, in contrast with the normal state, the hepatic bile may be supersaturated postprandially. Faecal bile acids and neutral sterols of cholesterol origin were decreased proportionately to the corresponding biliary lipid secretion rates. In fact, both biliary and faecal steroid outputs were only about a half or less than those in the controls, indicating that the fractional absorption was not changed but absolute absorption and faecal steroid excretion were low in patients with chronic cholestatic liver disease. Thus, despite low cholesterol and bile acid absorption, cholesterol and bile acid synthesis is low. A negative correlation between faecal steroids and serum cholesterol suggests that the high serum cholesterol level contributed to regulation of cholesterol synthesis.

Marked abnormalities in cholesterol and bile acid metabolism have been reported in patients with severe chronic liver diseases. In non-cholestatic cirrhosis the production of cholesterol holding capacity of the bile is higher than in control subjects. In liver failure in general the biological half-life of bile acids is prolonged, the pool size diminished, and the synthesis of bile acids is markedly reduced. Our previous studies on biliary lipid composition and faecal steroid excretion suggested that the patients with severe forms of chronic active hepatitis and primary biliary cirrhosis have a low biliary lipid secretion, resulting in decreased faecal steroid output. With this background the present study was designed to obtain more detailed information on the hourly biliary secretion rates of cholesterol, bile acids and phospholipids in patients with chronic cholestatic liver disease. This is of particular interest as the prevalence of gall stones is increased in patients with cirrhosis of the liver.

Methods

PATIENTS

The series included eight patients with variable severity of primary biliary cirrhosis, one patient with a cholestatic form of chronic active hepatitis, and one patient with sclerosing cholangitis. Six of the patients (nos. 1, 2, 4, 5, 6, and 9, Table 1) were the same as reported in our previous study. Seven healthy medical students served as controls. Informed consent was obtained before the studies both from patients and controls. The diagnosis of primary biliary cirrhosis was based on typical clinical, biochemical, and histological findings as published in detail before and the diagnostic criteria were similar to those reported by Sherlock and Scheuer. The patient with chronic active hepatitis was HbAg negative. His diagnosis was based on the accepted histological criteria. The case represented, however, the cholestatic form of the disease characterised by the presence of orcein positive copper protein accumulations in histological liver specimens. The diagnosis of sclerosing cholangitis was confirmed by endoscopic retrograde cholangiography. The symptoms had lasted for over a year in every case. The summary of the clinical and

* This study was presented in part at the VIIIth World Congress of Gastroenterology, Madrid, Spain, June 1978. (Abstracts of papers, p.157).
† Address for reprint requests: Professor TA Miittinen, Second Department of Medicine, University of Helsinki, SF-00290 Helsinki 29, Finland.

Received for publication 26 March 1982

Gut, 1982, 23, 931–938
Table 1  *Clinical data on patients with chronic cholestatic liver disease and control subjects*

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Body weight (kg)</th>
<th>Body weight Relative (%)</th>
<th>Alb* g/l (38-51)</th>
<th>Alat (U/l) (8-45)</th>
<th>P+P (75-100)</th>
<th>AFOS U/l (60-240)</th>
<th>LAP U/l (18-48)</th>
<th>γGT U/l (6-20)</th>
<th>Bil mmol/l (&gt;6-8 mg/min)</th>
<th>BSP-Tm mmol/l (4.4-7.2)</th>
<th>Chol mmol/l (0.4-1.7)</th>
<th>TG mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>22</td>
<td>91.0</td>
<td>1.19</td>
<td>34.0</td>
<td>130</td>
<td>82</td>
<td>790</td>
<td>138</td>
<td>485</td>
<td>11</td>
<td>8</td>
<td>7.0</td>
<td>7-27</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>67</td>
<td>60.2</td>
<td>1.19</td>
<td>29.5</td>
<td>46</td>
<td>91</td>
<td>895</td>
<td>108</td>
<td>83</td>
<td>5.5</td>
<td>6</td>
<td>6.1</td>
<td>1-03</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>31</td>
<td>58.3</td>
<td>0.08</td>
<td>31.4</td>
<td>97</td>
<td>96</td>
<td>1055</td>
<td>236</td>
<td>505</td>
<td>16</td>
<td>1-2</td>
<td>9.0</td>
<td>1-16</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>55</td>
<td>65.0</td>
<td>1.20</td>
<td>25.3</td>
<td>92</td>
<td>107</td>
<td>1152</td>
<td>143</td>
<td>140</td>
<td>39</td>
<td>2-4</td>
<td>10-7</td>
<td>1-21</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>51</td>
<td>65.0</td>
<td>1.18</td>
<td>24.5</td>
<td>96</td>
<td>59</td>
<td>626</td>
<td>107</td>
<td>33</td>
<td>17</td>
<td>2-3</td>
<td>6-1</td>
<td>0-50</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>66</td>
<td>55.3</td>
<td>0.95</td>
<td>28.1</td>
<td>132</td>
<td>87</td>
<td>517</td>
<td>79</td>
<td>107</td>
<td>63</td>
<td>2-3</td>
<td>4-8</td>
<td>1-33</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>51</td>
<td>53.0</td>
<td>1.00</td>
<td>23.5</td>
<td>64</td>
<td>87</td>
<td>1201</td>
<td>98</td>
<td>50</td>
<td>330</td>
<td>1-4</td>
<td>10-6</td>
<td>2-42</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>41</td>
<td>58.2</td>
<td>1.08</td>
<td>18.0</td>
<td>338</td>
<td>114</td>
<td>2656</td>
<td>316</td>
<td>320</td>
<td>56</td>
<td>0-89</td>
<td>9-9</td>
<td>0-82</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>35</td>
<td>54.7</td>
<td>0.94</td>
<td>30.7</td>
<td>333</td>
<td>93</td>
<td>1758</td>
<td>373</td>
<td>246</td>
<td>67</td>
<td>0-74</td>
<td>15-4</td>
<td>2-04</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>37</td>
<td>64.6</td>
<td>1.09</td>
<td>29.4</td>
<td>165</td>
<td>99</td>
<td>1477</td>
<td>248</td>
<td>360</td>
<td>19</td>
<td>0-56</td>
<td>8-7</td>
<td>1-11</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td>8/2</td>
<td>±4-6</td>
<td>±0-03</td>
<td>±1-5</td>
<td>±32-8</td>
<td>±4-7</td>
<td>±200-4</td>
<td>±32-4</td>
<td>±56-0</td>
<td>±30-3</td>
<td>±1-0</td>
<td>±1-0-23</td>
<td>±0-2-9</td>
</tr>
<tr>
<td>Controls</td>
<td></td>
<td>3/4</td>
<td>±0-04</td>
<td>±0-03</td>
<td>±0-13</td>
<td>±3-8</td>
<td>±0-4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>±1-3</td>
<td>±1-0</td>
<td>±0-06</td>
</tr>
</tbody>
</table>

The diagnosis of the patients: nos 2-5 and 7-10 primary biliary cirrhosis, no. 1 sclerosing cholangitis, no. 6 cholestatic form of chronic active hepatitis.

* Alb = serum albumin, Alat = serum alanine aminotransferase, P+P = plasma prothrombin, AFOS = serum alkaline phosphatase, LAP = serum leucine aminopeptidase, γGT = serum gamma-glutamyl transferase, Bil = serum bilirubin, BSP-Tm = transport maximum for bromosulphophthalein, Chol = serum cholesterol, TG = serum triglycerides. The normal ranges of laboratory data are given in parentheses.

† Statistically significant difference (p<0.01 or less) from controls.

Procedures

All the patients and controls were hospitalised and placed on a standard diet. This low-cholesterol (1-5 mg/kg/day) solid-food diet contained 40% of energy as fat, 45% as carbohydrate, and 15% as protein. The daily energy content of the diet was 30-35 kcal/kg of body weight, and was adjusted to maintain a constant body weight during the studies. The fat content of the standard diet consisted of meat, lard, soya oil, and margarine. As unabsorbable markers 600 mg of Cr2O3 and beta-sitosterol were each divided into three daily doses so that corrections could be made respectively for faecal flow and degradation of cholesterol during intestinal transit. After the patients had been on the diet and the markers for five to seven days a single two to three day faecal collection was made.

Thereafter the hepatic lipid secretion into the duodenum was determined according to Grundy and Metzger. After an overnight fast a two lumen radio-opaque tube (type AN 20, HW Andersen Products, Ltd, England) was positioned under fluoroscopic control into the second part of the duodenum. To make the gall bladder contract each patient received cholecystokinin (pancreozymin, Boots Company, Ltd, England) 2 units per kg of body weight, up to a maximum dose of 100 units per patient, in 20 ml of physiological saline intravenously. The liquid formula used in the study was prepared by sonication from 20 ml olive oil, 20 g fat-free milk powder, 4.5 g glycerol-1-mono-oleate (Fluka SG, Switzerland) and 200 ml water. The energy content of the formula was 1.3 kcal/ml. The formula contained 4 g polyethylene glycol 4000 (Fluka AG, Switzerland) as a non-absorbable marker. The formula with markers was infused at a rate of 30 ml/h into the duodenum via the proximal outlet of the tube with an infusion pump. Samples of 5-10 ml were aspirated hourly through outlets, which were located 15-20 cm more distally in the duodenum. Collections were performed up to six to eight hours. The samples obtained were placed in a water bath at 70°C for five minutes to destroy the lipase activity and stored at -20°C until analysed. The biliary secretion rates of cholesterol, bile acids, and phospholipids into the duodenum were calculated according to Grundy and Metzger from the samples collected at four to eight hours of perfusion.

Analytical Methods

The automated methods of our hospital laboratory were used to estimate serum concentrations of albumin, alanine aminotransferase, plasma prothrombin, alkaline phosphatase, bilirubin, cholesterol, and triglycerides. Transport maximum for bromosulphophthalein was measured according to Wheeler et al. Hepatic cholesterol from duodenal fluid was analysed as described by Miettinen et al. An aliquot of petroleum ether extract of saponified hepatic lipids, containing 5-α-
cholestanol as an internal standard, was taken for the
gas liquid chromatography analysis of cholesterol and
β-sitosterol. Hepatic bile acids were determined
with an enzymatic method.19 Hepatic phospholipids were measured by the method of Bartlett20 using
the Fiske-Subbarow reagent.21 Faecal bile acids were
measured by gas liquid chromatography as described by Grundy et al.22 except that the thin
layer chromatography step was omitted. Faecal neutral sterols derived from cholesterol and dietary
plant sterols and their bacterial conversion products
were measured by gas liquid chromatography after
thin layer chromatography separation according to
Miettinen et al.18 Chromic oxide (Cr₂O₃) was
determined as reported by Bolin et al.23 Polyethylene glycol was determined according to
Hyden.24 Faecal fat was measured according to the
method of van de Kamer et al.25

STATISTICS
The results are given as means and standard error
of mean (SE). The regression analyses were carried
out by the method of least squares. The statistical
significance of the difference was estimated by
Student’s t test.

Results

SERUM LIPIDS
The mean serum cholesterol and triglyceride levels
were significantly raised in the patients with chronic
cholestatic liver disease (Table 1). Only a few
patients, however, had a marked hypercholesterolaemia and only three patients were actually
hypertriglyceridaemic.

BILIARY LIPIDS
The mean biliary secretion rates of cholesterol, bile
acids and phospholipids were in the patients only 52,
38, 35%, respectively, of those in the controls
(Table 2). The hourly secretion rates of bile acids correlated significantly with those of cholesterol and phospholipids in both groups (Fig. 1). The mean
molar percentage of cholesterol was markedly raised
in the hepatic bile of the patients. The molar percentage plotted against the respective hourly
output of bile acids (Fig. 2) showed a negative
correlation in both groups and demonstrates the
high molar percentage of cholesterol (supersaturation) at the low bile acid output in the
patients. At higher bile acid secretion rates, however, around 10 μmol kg⁻¹h⁻¹, for instance, the
molar percentage of cholesterol tends to be even
lower in the patients than in the controls.

The plot of the biliary lipid secretion rates against
the liver function tests of Table 1 revealed a
significant correlation between the phospholipid
secretion and the maximal BSP transport (r = 0.78;
p < 0.01, n = 10). In addition, serum bilirubin was
positively correlated with the molar percentage of

Table 2  Biliary and faecal lipids in patients with chronic cholestatic liver disease and controls

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>Biliary secretion rates (mg/kg/h)</th>
<th>Molar percentage of biliary lipids</th>
<th>Faecal fat (g/day)</th>
<th>Faecal steroids (mg/kg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chol</td>
<td>BA</td>
<td>PL</td>
<td>Chol</td>
</tr>
<tr>
<td>Liver patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.27</td>
<td>1.53</td>
<td>0.07</td>
<td>10.3</td>
</tr>
<tr>
<td>2</td>
<td>0.32</td>
<td>3.14</td>
<td>0.05</td>
<td>8.1</td>
</tr>
<tr>
<td>3</td>
<td>0.76</td>
<td>2.30</td>
<td>0.07</td>
<td>19.7</td>
</tr>
<tr>
<td>4</td>
<td>0.22</td>
<td>4.18</td>
<td>0.03</td>
<td>4.8</td>
</tr>
<tr>
<td>5</td>
<td>0.41</td>
<td>3.50</td>
<td>0.05</td>
<td>9.3</td>
</tr>
<tr>
<td>6</td>
<td>0.22</td>
<td>2.34</td>
<td>0.02</td>
<td>8.1</td>
</tr>
<tr>
<td>7</td>
<td>0.19</td>
<td>0.32</td>
<td>0.02</td>
<td>25.3</td>
</tr>
<tr>
<td>8</td>
<td>0.12</td>
<td>0.75</td>
<td>0.02</td>
<td>10.9</td>
</tr>
<tr>
<td>9</td>
<td>0.19</td>
<td>1.24</td>
<td>0.03</td>
<td>10.7</td>
</tr>
<tr>
<td>10</td>
<td>0.24</td>
<td>0.87</td>
<td>0.02</td>
<td>18.0</td>
</tr>
<tr>
<td>Mean±SE</td>
<td>0.29±0.06*</td>
<td>2.02±0.41*</td>
<td>0.038±0.006*</td>
<td>12.5±2.0*</td>
</tr>
<tr>
<td>Controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.71</td>
<td>4.90</td>
<td>0.11</td>
<td>10.4</td>
</tr>
<tr>
<td>2</td>
<td>0.46</td>
<td>6.95</td>
<td>0.10</td>
<td>5.5</td>
</tr>
<tr>
<td>3</td>
<td>0.47</td>
<td>5.13</td>
<td>0.09</td>
<td>7.2</td>
</tr>
<tr>
<td>4</td>
<td>0.85</td>
<td>5.29</td>
<td>0.12</td>
<td>11.4</td>
</tr>
<tr>
<td>5</td>
<td>0.37</td>
<td>4.24</td>
<td>0.05</td>
<td>7.3</td>
</tr>
<tr>
<td>6</td>
<td>0.38</td>
<td>3.77</td>
<td>0.07</td>
<td>7.7</td>
</tr>
<tr>
<td>7</td>
<td>0.66</td>
<td>7.95</td>
<td>0.20</td>
<td>6.1</td>
</tr>
<tr>
<td>Mean±SE</td>
<td>0.56±0.07</td>
<td>5.46±0.56</td>
<td>0.11±0.02</td>
<td>7.9±0.8</td>
</tr>
</tbody>
</table>

Chol = cholesterol, BA = bile acids, PL = phospholipids, NS = neutral steroids, BA = bile acids.
* Statistically significant difference (p < 0.05 or less) from controls.
Fig. 1  Relationship between biliary outputs of cholesterol (left) and phospholipids (right) for patients with chronic cholestatic liver disease (above) and normal controls (below). Each circle represents an individual hourly output of the biliary lipids.

Fig. 2  Relationship between molar percentage of biliary cholesterol and biliary bile acid secretion in patients with chronic cholestatic liver disease (●) and in controls (○). Each circle represents an individual hourly value of the biliary lipids.

Biliary cholesterol \((r=0.70; p<0.02; n=10)\) and phospholipids \((r=0.63; p<0.01; n=17)\) positively with serum triglyceride levels. For serum cholesterol these correlations were not significant.

**Fecal Fat and Sterols**

The mean faecal fat was higher in the patient group than in the controls. An increased faecal fat (7 g/day) was found, however, in three patients only (Table 2).
Table 3  Correlation coefficients (r) of biliary and faecal lipids with some serum parameters in controls and in patients with chronic cholestatic liver disease

<table>
<thead>
<tr>
<th></th>
<th>Faecal bile acids</th>
<th>Faecal neutral steroids</th>
<th>Faecal total steroids</th>
<th>Serum cholesterol</th>
<th>Serum triglycerides</th>
<th>Serum albumin</th>
<th>Bromosulphophthalein transport maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biliary cholesterol secretion</td>
<td>0·23†</td>
<td>0·66*</td>
<td>0·68*</td>
<td>-0·23</td>
<td>-0·25</td>
<td>0·41</td>
<td>0·39</td>
</tr>
<tr>
<td></td>
<td>0·60*</td>
<td>0·75*</td>
<td>0·75*</td>
<td>-0·47</td>
<td>-0·49*</td>
<td>0·10</td>
<td>0·50</td>
</tr>
<tr>
<td>Biliary bile acid secretion</td>
<td>-0·05</td>
<td>0·23</td>
<td>0·13</td>
<td>-0·36</td>
<td>-0·49*</td>
<td>0·61*</td>
<td>0·65*</td>
</tr>
<tr>
<td></td>
<td>0·55*</td>
<td>0·75*</td>
<td>0·75*</td>
<td>-0·61*</td>
<td>0·49*</td>
<td>0·12</td>
<td>0·60</td>
</tr>
<tr>
<td>Biliary phospholipid secretion</td>
<td>0·70*</td>
<td>0·42</td>
<td>0·86*</td>
<td>-0·51*</td>
<td>0·39</td>
<td>-0·45</td>
<td>0·17</td>
</tr>
<tr>
<td></td>
<td>0·70*</td>
<td>0·80*</td>
<td>0·82*</td>
<td>-0·51*</td>
<td>0·39</td>
<td>-0·45</td>
<td>0·17</td>
</tr>
<tr>
<td>Faecal bile acids</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0·04</td>
<td>0·68*</td>
<td>-0·45</td>
<td>0·78*</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0·45</td>
<td>0·17</td>
<td>-0·45</td>
<td>0·78*</td>
</tr>
<tr>
<td>Faecal neutral sterols</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-0·51*</td>
<td>-0·35</td>
<td>0·01</td>
<td>0·55</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-0·65*</td>
<td>-0·62*</td>
<td>-0·65*</td>
<td>0·55</td>
</tr>
<tr>
<td>Total faecal steroids</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-0·51*</td>
<td>-0·35</td>
<td>0·01</td>
<td>0·55</td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-0·51*</td>
<td>-0·35</td>
<td>0·01</td>
<td>0·55</td>
</tr>
</tbody>
</table>

† The upper number gives the r-value for the patients only.
‡ The lower number gives the r-value for the pooled material of controls and patients.
* Statistically significant (p<0.05 at least) correlation.

The daily output of faecal bile acids, neutral steroids, and total steroids was significantly lower in the patients than in the controls. The mean respective values were only 56, 40, and 52% of those in the controls.

The correlations in Table 3 and Fig. 3 indicate that, in general, the lower the faecal steroid excretion the lower also was the biliary lipid secretion rate and the higher were the serum cholesterol and triglyceride levels. Thus, hypercholesterolaemia and hypertriglyceridaemia were associated with impaired cholesterol elimination and reduced cholesterol synthesis (sterol balance values). Furthermore, the maximal BSP transport correlated positively with faecal steroids and bile acids (Table 3).

Discussion

Findings on the biliary lipid composition and the faecal steroid excretion in patients with primary biliary cirrhosis and chronic active hepatitis have
suggested low biliary lipid secretion rates in the severe forms of these diseases. Direct measurements of the biliary lipid secretion rate in the present study on patients with varying severity of mainly primary biliary cirrhosis show this suggestion to be true. In contrast, however, with the observations on the low molar percentage of cholesterol in the fasting gall bladder bile of the hepatic bile obtained during the hepatic secretion exhibited a high molar percentage (12.5% vs. 7.9% in the controls) in the present patients. In addition, fasting gall bladder bile samples were previously analysed and reported (7) for six of the patients of the present study (patients nos 1, 2, 4, 5, 6, and 9). The molar percentage of cholesterol for these six patients was significantly higher in the hepatic bile of the present study (8.6%±0.9 (SEM) ) than in the fasting gall bladder bile of our previous study (5.6%±0.9 (7)) (p<0.025, paired t test). Thus, in severe cholestatic liver disease the hepatic bile appears to be strongly supersaturated during active enterohepatic circulation of bile acids mainly because bile acids are retained in the circulation. During night time and during the fasting state in general the hepatic bile of these patients is apparently less saturated with cholesterol, resulting in the low molar percentage in the gall bladder bile. In cholestatic liver disease the situation may thus be inverse to the normal state in which the hepatic bile is supersaturated in fasting state and undersaturated postprandially. Therefore, the situation differs from that in the patients with moderately advanced alcoholic cirrhosis in which the biliary lipid secretion rates are not disturbed and the molar percentages of cholesterol are normal both in the gall bladder bile and in hepatic bile obtained during biliary secretion measurements. In severe alcoholic cirrhosis, in which the biliary lipid secretion is low, the cholesterol saturation of the gall bladder bile is low but appears to be normal (molar % cholesterol 5.2 vs 4.3 in the controls) during biliary lipid secretion measurements.

The finding of low fasting and high postprandial cholesterol saturation of bile in patients with chronic liver disease may be clinically important. The prevalence of gall stones is increased in patients with cirrhosis of the liver. In contrast, however, with the general population where the majority of gall stones are of the cholesterol type cirrhotic patients have principally pigment stones. Therefore, it is possible that the inverse situation of supersaturated postprandial and undersaturated fasting bile observed in the patients of the present study is actually beneficial in the prevention of cholesterol gall stone formation in patients with liver disease and low biliary lipid secretion.

Ordinary liver function tests are weakly associated with biliary lipid secretion in patients with chronic cholestatic liver disease. Significant correlations were observed, however, between the serum cholesterol and triglyceride values on the one hand and the biliary and faecal steroid outputs on the other hand. Thus, in general, the development of hyperlipidaemias appears to be associated with impaired biliary and faecal steroid output in cholestatic liver disease.

Faecal bile acids and neutral sterols of cholesterol origin have been reported to be decreased in patients with chronic cholestatic liver disease and these findings were confirmed in the present study. Urinary bile acids are frequently raised, but this route of bile salt elimination is minor compared with faecal excretion. This indicates that bile acid and cholesterol synthesis are decreased in patients with cholestatic liver disease, a finding supported by earlier observations. The positive correlation of faecal steroid outputs with the biliary lipid secretion rates suggests that low biliary secretion of cholesterol and bile acids determined mainly the low faecal excretion and not the increased fractional absorption of these steroids. In fact, as compared with the controls the biliary secretion rates and faecal steroid excretion were decreased by about a factor of two, as if the relative absorption had been unchanged. Calculations of the relative absorption of both bile acids (96.5%) and cholesterol (25.4%) (from the dietary, biliary, and faecal steroid data) of the patients with chronic cholestatic liver disease actually revealed similar values to those of the controls (bile acids: 96.8%; cholesterol 24.9%). Thus, the mean absolute absorption of both cholesterol (2.1 mg/kg/day for the patients vs 3.2 mg/kg/day for controls) and bile acids (47 mg/kg/day for the patients vs 127 mg/kg/ day for controls) had decreased proportionately to the decrease in biliary secretion. Low absorption of cholesterol and bile acids should have stimulated cholesterol synthesis. That the synthesis was actually low may be due to the liver damage or to an inhibitory effect of increased serum cholesterol level on hepatic cholesterol synthesis. Thus, patients with chronic cholestatic liver disease are characterised by impaired biliary lipid output frequently associated with high serum lipid values, normal fractional absorption but clearly decreased absolute absorption of cholesterol and bile acids, and decreased cholesterol and bile acid synthesis.

The absence of steatorrhoea in the present series, also shown in our previous studies, might indicate that, despite the clear-cut decrease of the biliary bile acid secretion, it was sufficient to maintain the intestinal bile acid level above the critical micellar

Kesäniemi, Salaspuro, Vuoristo, and Miettinen
Biliary lipid secretion

centration during fat digestion. Fatty acids are, however, absorbed to some extent along the small intestine also without micellar solubilisation.\textsuperscript{32, 33} Thus faecal fat can be only modestly increased in patients with liver disease and severe disturbance of micellar formation.\textsuperscript{1} Micellar solubilisation is a prerequisite of cholesterol absorption.\textsuperscript{34, 35} The normal percentage of cholesterol absorption in the patients with cholestatic liver disease suggests that, for the small intestinal cholesterol pool of these patients, the bile acid secretions were sufficient to facilitate micellar solubilisation of cholesterol. It can be speculated that on a higher cholesterol intake the relative cholesterol absorption would have been reduced.

Supported by the National Council for Medical Research of Finland. Mrs Marja Aarnio, Mrs Leena Kaipiainen, Mrs Liisa Kuhta, Mrs Eeva Gustafsson, and Miss Tuula Moisio are acknowledged for technical and secretarial assistance.

References

23 Bolin DW, King RP, Klosterman EW. A simplified method for the determination of chromic oxide (Cr₂O₃) when used as an index substance. \textit{Science} 1952; 116: 634–35.
26 Bergman von K, Mok HYI, Hardison WGM, Grundy...


31 Raedsch R, Lauterburg B, Hofmann AF. Personal communication.

32 Hofman AF. A physiocochemical approach to the intraluminal phase of fat absorption. *Gastroenterology* 1966; 50: 56-64.


Biliary lipid secretion in chronic cholestatic liver disease.

Y A Kesäniemi, M P Salaspuro, M Vuoristo and T A Miettinen

Gut 1982 23: 931-938
doi: 10.1136/gut.23.11.931

Updated information and services can be found at:
http://gut.bmj.com/content/23/11/931

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/